Overview

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
Phase:
PHASE2
Details
Lead Sponsor:
Guangdong Provincial People's Hospital
Treatments:
Anthracyclines
Anthraquinones
Azacitidine
Cytarabine
Daunorubicin
Idarubicin
Mitoxantrone
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
venetoclax